Neosem on Korea Invest Insights

Neosem CXL Tester Thesis: Gen6 SSD Orders and 2026 Inflection

Sat, 25 Apr 2026 19:20:00 +0900

SemiScope deep dive. Neosem is not a broad semiconductor-equipment basket. It is a focused ATE name sitting at the intersection of PCIe Gen6 SSD, CXL memory expansion, server DIMM automation and the next test bottlenecks in AI data-center memory.

TL;DR

Neosem (253590 KQ) is an ATE company, not an IP company. It sells semiconductor post-process test equipment: PCIe SSD testers, CXL memory testers, server DIMM automation testers, and burn-in testers. If OpenEdges is the upstream IP option in the CXL stack, Neosem is the downstream equipment option that gets paid when memory makers order tools.
The core franchise is interface-transition testing. PCIe Gen5 SSD testers, CXL 1.1/2.0 memory testers, and the coming PCIe Gen6 / CXL 3.1 cycle all share one theme: when a new high-speed memory interface becomes real, the test problem becomes harder and equipment content rises.
2025 was ugly, but that is exactly why the setup is interesting. Revenue fell 39.3% YoY to KRW 63.9B, operating profit fell 75.3% to KRW 4.1B, and OPM compressed to 6.4%. Memory capex pauses and heavier R&D hit at the same time. But management’s November IR pointed to a sharp order rebound from late August, with September to November orders reportedly running at roughly twice the January to August cumulative level.
The 2026-2027 trigger stack is unusually dense. Gen6 SSD tester demos, CXL 3.1 production tester deliveries, GEMINI3 for SOCAMM, BX burn-in optionality, and overseas customer expansion create multiple ways for revenue to recover. The cleanest near-term signal is whether late-2025 orders convert into 1Q26/2Q26 revenue.
Investment view: event-driven turnaround plus cycle beta. Neosem is not yet a smooth compounder. It is a lumpy equipment stock tied to memory capex and customer timing. But first-mover references in CXL and a potentially cleaner competitive field in SSD testers make it one of the most direct Korean listed ways to underwrite the next interface-test cycle.

Why Neosem Matters

The semiconductor market loves to talk about compute: GPUs, AI accelerators, HBM stacks, CXL memory pools and SSD capacity. But before those devices enter servers, they have to be tested. Not sampled. Not spot-checked. Tested at production scale.

That is Neosem’s lane.

Neosem makes automated test equipment, or ATE, for memory and storage devices after fabrication and packaging. Its tools are used to verify whether SSDs, CXL memory devices, DIMMs and related modules behave correctly before shipment. The more mission-critical the system, the less tolerance there is for latent defects. A bad storage or memory device in an AI server can create system-level instability, and the cost of failure rises as data-center memory architectures become more complex.

The company’s strategic sweet spot is not generic testing. It is testing around new high-speed interfaces. PCIe 4.0 moved to PCIe 5.0. PCIe 5.0 moves to PCIe 6.0. CXL 1.1 moved to CXL 2.0, and the market is preparing for CXL 3.1. Each transition increases speed, protocol complexity, signal-integrity pressure, error handling and validation burden.

That is why Neosem is interesting. It has built a reputation as an early commercializer of production testers for new interface standards. It was early in PCIe-based SSD testing. It commercialized CXL 1.1 and 2.0 memory testers and shipped production tools to Samsung Electronics. And it is now trying to extend that first-mover position into CXL 3.1 and Gen6 SSD testers.

The stock’s central debate is simple: was 2025 a structural deterioration, or was it a capex pause before a new order cycle?

My read: 2025 was a real downcycle, not a rounding error. But the order-cycle inflection is also real enough to monitor closely. Neosem is one of the cleaner Korean event-driven plays on the 2026 interface-test recovery.

What Neosem Actually Sells

Neosem’s products fall into four practical buckets.

Product family	What it tests	Why it matters
PCIe SSD Tester	Enterprise and data-center SSDs using PCIe Gen4/Gen5 and future Gen6 interfaces.	AI servers need faster storage and higher reliability. Interface speed increases test complexity.
CXL Memory Tester	CXL memory devices and related memory-expansion products.	CXL links CPUs, memory and accelerators under a coherent memory architecture. Validation has to cover protocol behavior, latency and error handling, not just simple signaling.
Server DIMM Automation / GEMINI	Server memory modules and automated chamber-style test workflows.	Server memory testing needs throughput, automation and reliability at volume.
Burn-in Tester / BX series	Memory components under stress conditions, including potential future HBM-related variants.	Burn-in screens for reliability under temperature, voltage and time stress. HBM-specific opportunity exists, but Neosem is not the leader today.

The clearest franchise today is SSD and module testing. KIRS materials put SSD Tester plus server DIMM Tester at 82.9% of 1H25 revenue. Component testing, including burn-in, appears to contribute roughly 10-15%, while CXL is not separately disclosed.

That lack of CXL disclosure matters. Investors often say “Neosem is a CXL equipment stock,” but the reported revenue line still blends SSD, DIMM, CXL and related equipment. CXL may become the highest narrative multiple product, but the current financial base is still broader than CXL alone.

2025 Financials - A Sharp Reset

Neosem’s 2025 numbers were not subtle.

Metric	2022	2023	2024	2025	2025 YoY
Revenue	KRW 74.7B	KRW 100.9B	KRW 105.2B	KRW 63.9B	-39.3%
Operating profit	KRW 8.4B	KRW 8.1B	KRW 16.5B	KRW 4.1B	-75.3%
Operating margin	11.2%	8.0%	15.7%	6.4%	-9.3pp
Net income	KRW 10.0B	KRW 8.3B	KRW 19.2B	KRW 4.8B	-74.8%

This was a classic equipment-cycle compression. Revenue fell as memory customers delayed or slowed inspection-equipment capex, while R&D and product-development costs did not fall in line. The company was spending for Gen6 SSD, CXL 3.1, SOCAMM automation and burn-in extensions while customers were still digesting prior capacity.

That is the dangerous side of the model. Equipment companies have operating leverage both ways. When orders accelerate, margins recover quickly. When orders pause, fixed engineering and support costs compress margins just as quickly.

The forward-looking piece is the order commentary. In the November 2025 IR, the company indicated that orders began rising sharply from late August, with September to November orders reportedly around twice the January to August cumulative level. Because equipment revenue recognition usually lags orders by roughly six to nine months, that points to a potential 2026 revenue recovery rather than a 2025 recovery.

The first hard test is 1Q26 and 2Q26. If quarterly revenue moves back toward the KRW 20B+ range, the market can treat the late-2025 order rebound as real. If not, the 2026 “record year” ambition needs to be discounted heavily.

The Moat - First-Mover Interface Validation

Neosem’s moat is not that no one else can build testers. Teradyne, Advantest, DI, Exicon and other test-equipment players exist. The moat is narrower: Neosem has been early at turning new interface standards into production-ready memory and SSD testers.

Moat axis	Assessment	Why
PCIe SSD tester position	High	Advantest reportedly exited the SSD tester business in January 2025, strengthening Neosem’s position in PCIe Gen5 SSD testers.
CXL production references	High	Neosem has commercial references in CXL 1.1 and 2.0 production testers supplied to Samsung Electronics.
Customer validation history	Medium-high	Device-specific validation data, firmware, debug history and customer line integration create switching friction.
Throughput / automation	Medium	GEMINI gives server DIMM automation exposure, but throughput leadership must be re-proven by generation.
Cost competitiveness	Medium	Korean equipment vendors can be cost-competitive, but global ATE vendors have scale and support depth.

The most important asset is validation history. In high-speed interface testing, the tool does not only need to generate signals. It needs to understand device behavior, test patterns, error modes, protocol timing, firmware corner cases and customer-specific production workflows. Once a memory maker has debugged a new device generation on a given tester platform, switching is not frictionless.

This is especially relevant in CXL. A CXL memory device is not just a faster DIMM. It has to work under memory semantics, cache coherency, latency constraints and system-level error handling. A production tester has to validate behavior that sits closer to system architecture than traditional memory testing.

That said, the moat is not permanent. CXL 3.1 may invite dual sourcing. Samsung, SK Hynix and Micron do not like single-vendor dependence if the category becomes large. Exicon, DI and global test vendors can push harder into the same opportunity. Neosem’s first-mover edge matters most if it turns into repeat production wins before rivals catch up.

Customer Map - Samsung, SK Hynix, Micron and the Export Question

The publicly visible customer base includes Samsung Electronics, SK Hynix and Micron. The challenge is that customer-by-customer revenue is not fully disclosed, and CXL-specific revenue is not separated.

Category	Customer / area	Product	Status	Confidence
Current production	Samsung Electronics memory	CXL 1.1 / 2.0 production memory tester and debug station	Production shipment references reported	High
Current production	Samsung Electronics memory	DDR5 DIMM tester	Production supply cited by sell-side	High
Current production	SK Hynix	BX burn-in tester	Order and revenue-recognition references cited by sell-side	High
Current production	Micron	SSD tester	Production supply history and 2023 supplier award reference	High
In progress	Samsung Electronics	CXL 3.1 production memory tester	Some 2026 first-half deliveries expected by market commentary	Medium-high
In progress	Samsung Electronics	Gen6 SSD tester	Demo testing underway, 2027 production target	Medium
In progress	Samsung / SK or broader memory ecosystem	HBM-focused BX burn-in variant	Company has discussed development consideration, but execution is unclear	Low-medium
In progress	NVIDIA memory ecosystem / memory makers	GEMINI3 for SOCAMM	Development for possible 2026 orders, but end-customer identity is unclear	Low-medium
Potential	Overseas new customers	Burn-in and SSD/CXL test tools	Management wants export expansion and a 2027 US$100M export milestone	Low-medium

The customer signal that matters most is Micron and broader overseas traction. If Neosem remains overwhelmingly tied to Samsung timing, the stock is a high-beta Samsung memory capex proxy. If overseas revenue share expands meaningfully, the multiple can broaden.

Management’s reference to a goal of reaching a US$100M export tower by 2027 is useful as an ambition marker, but I would treat it as an execution checkpoint rather than a base-case assumption. The observable metric is overseas revenue share in quarterly and annual filings.

Trend Impact Matrix

Trend	Impact	Investment read-through
AI server capex and PCIe 6.0 / Gen6 SSD	Strong tailwind	Faster data-center SSDs need new test coverage. If Advantest remains out of SSD testers, Neosem’s competitive position can be unusually clean.
CXL memory pooling and expansion	Strong tailwind	CXL 3.1 moves the category closer to scaled deployment. Neosem’s CXL 1.1/2.0 references are a real first-mover asset.
NVIDIA SOCAMM adoption	Tailwind	GEMINI3 could open a new automation category if SOCAMM becomes a real volume standard. Timing and market size remain unclear.
HBM package-test demand	Neutral to tailwind	BX burn-in has optionality, but TechWing and Advantest are more central in HBM test today. Neosem is not the clean HBM tester leader.
Burn-in integration and high-density testing	Tailwind with competition	BX includes low-frequency test functionality, but Exicon’s CLT positioning and DI’s burn-in strength increase competitive pressure.
Samsung memory capex recovery	Tailwind	Samsung is a key customer and CXL/Gen6 timing matters directly.
SK Hynix capex cycle	Neutral to mild tailwind	Neosem has burn-in exposure, but HBM-specific test leadership appears elsewhere for now.
US-China export controls	Neutral to mild headwind	Direct China exposure appears limited, but memory makers’ capex allocation can shift with geopolitics.
Korean ATE localization	Tailwind	Domestic memory makers benefit from local equipment optionality in strategically important test categories.

The most important distinction is between “CXL adoption” and “CXL revenue timing.” CXL market forecasts can look huge. But Neosem only monetizes when memory makers order production testers, not when the industry publishes a TAM chart. The sequence is standard finalization, device development, customer qualification, pilot tools, production tools, then revenue.

Quantum-Jump Triggers

Trigger 1 - Gen6 SSD tester production adoption

This is the highest-quality trigger because Neosem already has a strong SSD tester base.

The definition is straightforward: PCIe 6.0 / Gen6 SSD testers move from demos and R&D tools into production lines at Samsung Electronics, Micron or both. Samsung’s PM1763-type Gen6 SSD roadmap and Micron’s Gen6 SSD certification trajectory are the underlying customer drivers.

The lead indicators:

2026 first-half R&D or pilot tester adoption;
2026 second-half production orders;
2027 revenue recognition;
evidence that Neosem remains the main or sole supplier.

If Gen5 single-supplier dynamics extend into Gen6, the upside can be meaningful. A 50%+ global share scenario in SSD testers is not impossible if rivals remain absent or late. The risk is that Teradyne or another ATE vendor expands aggressively into PCIe 6.0, or that Advantest re-enters despite its reported exit.

Trigger 2 - CXL 3.1 production tester cycle

CXL 3.1 is the more narrative-powerful trigger.

Neosem already has CXL 1.1 and CXL 2.0 production references. The next question is whether that history converts into CXL 3.1 production tester share as Samsung, SK Hynix and eventually Micron scale CXL memory products.

The lead indicators:

first CXL 3.1 production tester delivery in 1H26;
disclosed customer, tool count or contract size;
evidence that CXL 3.1 is not limited to engineering samples;
repeat orders in late 2026 and 2027.

The bull case is that CXL testers carry higher ASP than conventional SSD testers because they must validate protocol behavior, memory semantics, latency and error handling. A production cycle could add hundreds of billions of won in cumulative opportunity over multiple years if CXL memory expansion becomes a real data-center category.

The risk is dual sourcing. Samsung and other memory makers may split CXL 3.1 between Neosem and rivals such as Exicon or DI. If that happens, the CXL story is still positive, but the monopoly-like narrative fades.

Trigger 3 - HBM-focused BX burn-in entry

This is the most uncertain trigger.

HBM4 and HBM4E should increase reliability-screening needs, especially as stack height rises and bonding complexity increases. Neosem’s BX burn-in tester has a conceptual route into HBM-specific variants, and the company has discussed the possibility of HBM-focused development.

But today, I would not underwrite Neosem as the HBM test leader. TechWing’s cube prober ecosystem and Advantest’s memory-test platform are more central to the current HBM test conversation. Some reports also point to other vendors’ similar equipment moving through Samsung qualification.

So the trigger has to be concrete:

formal announcement of an HBM-specific BX variant;
qualification entry at Samsung or SK Hynix;
production order tied to HBM4 or HBM4E.

Until then, HBM is optionality, not the core thesis.

Trigger 4 - GEMINI3 and SOCAMM

SOCAMM, or Small Outline Compression Attached Memory Module, is a potential new memory-module form factor linked to NVIDIA ecosystem requirements and compact AI compute platforms. If SOCAMM becomes a volume standard, module automation and testing needs can create a new category for Neosem’s GEMINI3.

The lead indicators:

memory makers announcing SOCAMM-related capex;
NVIDIA platform specifications becoming stable enough for volume production;
Neosem showing GEMINI3 demos or early orders;
revenue contribution separated or discussed in filings.

The risk is standardization. If SOCAMM remains narrow, proprietary or low-volume, GEMINI3 may be a useful product but not a company-changing product.

Risk Map

Risk	Why it matters	What to watch
Customer concentration	Equipment revenue can swing with a few memory-maker decisions.	Samsung and Micron order timing, overseas revenue share, backlog tone.
Capex-cycle dependence	2025 showed how quickly revenue and margins can fall when customers pause spending.	1Q26 and 2Q26 revenue conversion from late-2025 orders.
CXL 3.1 competition	First-mover references may not guarantee single-supplier status.	Exicon, DI and global vendors’ CXL tester wins.
HBM follow-through risk	Neosem may miss the richest HBM test sub-cycle if it remains late.	HBM-specific BX development and qualification news.
R&D cost pressure	Gen6 SSD, CXL 3.1, BX and GEMINI3 all require spending before revenue.	OPM recovery versus continued engineering expense.
Forecast credibility	2025 sell-side forecasts were far too high versus actual results.	Management guidance versus order disclosures and recognized revenue.

The last point matters. A January 2025 sell-side forecast reportedly expected 2025 revenue of about KRW 131.5B, up 28%. Actual 2025 preliminary revenue was KRW 63.9B, down 39%. That miss is not just a modeling error; it is a reminder that equipment stocks can move from “next year’s record high” to “capex delay” very quickly.

For 2026, I would use management optimism as a hypothesis, not a conclusion.

Five Checkpoints for the Next Two Quarters

1Q26 revenue recovery. If the late-2025 order rebound is real, revenue should start recovering. A quarterly revenue print above KRW 20B would be an important signal.
CXL 3.1 production tester delivery. A first-half 2026 Samsung-related CXL 3.1 production shipment would validate the CXL transition story.
Gen6 SSD tester order visibility. Watch for Samsung Gen6 SSD production-order timing in 2H26 and whether Neosem remains the main supplier.
HBM-specific BX decision. A formal HBM-focused development or qualification announcement would add a new optionality leg; silence keeps HBM outside the core thesis.
Export share and Micron traction. Evidence of overseas revenue growth is the difference between a Samsung-cycle proxy and a more global test-equipment franchise.

Valuation Frame

I would value Neosem less like a smooth quality compounder and more like a cycle-and-event option.

Scenario	What has to happen	Investor read-through
Bear case	Late-2025 orders fail to convert, CXL 3.1 is delayed or dual-sourced heavily, Gen6 SSD orders slip, R&D keeps margins near mid-single digits.	2025 was not a temporary trough; the stock remains a volatile small-cap equipment name.
Base case	1Q26/2Q26 revenue recovers, CXL 3.1 pilot shipments occur, Gen6 SSD remains on track for 2027, margins rebuild toward low double digits.	Neosem can rerate as a credible interface-test recovery play.
Bull case	Gen6 SSD tester single-supplier dynamics extend, CXL 3.1 production orders scale, Micron/overseas share rises, and one of SOCAMM or HBM burn-in becomes material.	Revenue can push beyond prior peak and the market can price a multi-product AI memory-test platform.

The key sensitivity is timing. A tester order delayed by six months can turn a record-year story into another disappointment. That is why the stock needs to be monitored through order conversion, not only product announcements.

Final Note - Allocator’s Frame

Neosem is a very different instrument from OpenEdges. OpenEdges is a long-duration IP royalty option. Neosem is a nearer-term equipment-cycle option tied to production tool orders. Both live near the CXL and AI memory architecture story, but the cash-flow timing is different.

That timing difference is why Neosem deserves attention now. The 2025 income statement already absorbed a hard downcycle. The company says orders turned up from late August. If those orders become revenue in 2026, the stock can shift from “failed 2025 guidance” to “next interface-test cycle leader.”

My view is constructive but conditional. Neosem belongs in the SemiScope watchlist as the clearest Korean listed ATE play on Gen6 SSD and CXL 3.1. But I would not let the CXL narrative outrun the evidence. The hard confirmations are simple: 1Q26 revenue recovery, CXL 3.1 production shipment, Gen6 SSD order visibility, and overseas customer expansion.

If those arrive together, Neosem is not just a rebound trade. It becomes a credible first-mover beneficiary of the next AI data-center memory test cycle.

Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.

Korean Memory ATE Stocks: Neosem, Exicon and OpenEdges Re-Ranked

Sat, 25 Apr 2026 18:00:00 +0900

SemiScope Part 1. Three Korean back-end test & IP names — Neosem (253590 KQ), Exicon (092870 KQ), OpenEdge Technology (394280 KQ) — re-ranked by timeframe rather than by a single CXL-purity prism. The conclusion that the consensus comparison reaches is internally consistent but reaches it through one lens; once you swap lenses, the rank order changes for the most actionable horizon.

TL;DR

Short-term momentum (the 2026 earnings inflection): Exicon > Neosem > OpenEdge. The consensus comp note that flags Exicon as an afterthought is reasoning purely through a CXL-purity prism. On a CLT-thesis prism — single-source DRAM low-frequency tester with Samsung’s final qualification cleared in late 2024 — Exicon is the cleanest J-curve entry of the three.
The 2024-2025 loss / revenue-decline reset is the most under-reflected fact in the consensus comp. Neosem revenue fell 39.3% YoY in 2025 with operating margin compressed to 6.4%. Exicon ran a KRW 15.9B operating loss in 2024. OpenEdge’s 3Q YTD operating loss of KRW 21.3B is widening, not shrinking. All three are in turnaround positioning — that means volatility before the inflection.
Long-term IP platform value (2027-2029): OpenEdge > Neosem > Exicon. Here the consensus is right. The caveat is that OpenEdge’s royalty mix at 0.4% of revenue means the J-curve inflection sits further out than the framing implies.

Bottom line — by timeframe, not by ranking:

Name	Position type	Entry timing	Key event
Exicon	Near-term J-curve bet (CLT volume-revenue recognition)	Now	1Q26 swing-to-profit stability, cumulative CLT install base
Neosem	Cycle turnaround + Gen6 / CXL 3.1 sole-source bet	After 1Q26 print	1Q26 revenue recovery + first CXL 3.1 mass-production order
OpenEdge	Long-dated IP-platform option (3-5 yr)	Scaled accumulation	First LPDDR6 license disclosure + royalty mix reaches 5%

The “Neosem = Core / OpenEdge = option / Exicon = afterthought” conclusion is coherent only under a single CXL-purity prism. Through a 2026 earnings momentum + sole-source moat prism, Exicon is the most attractive near-term name — the central re-evaluation of this report.

1. What the Consensus Comp Missed

The consensus comparison doc treats one-axis prism (CXL substitutability) as the binding constraint. Three under-weighted facts shift the picture.

1-1. Neosem (253590 KQ)

Item	Consensus comp	SemiScope addition
2025 results	Not stated explicitly	Revenue KRW 63.9B (-39.3% YoY), operating profit KRW 4.1B (-75.3% YoY), OPM 6.4% — a meaningful self-cycle slowdown
Advantest SSD ATE exit	Not mentioned	Advantest withdrew from SSD ATE in Jan 2025 → Gen5/Gen6 SSD Tester is effectively a sole-source structure for Neosem
Nov 2025 IR guidance	Not mentioned	Order momentum surged from late August. Sep-Nov bookings ran ~2x the Jan-Aug pace. Company guides to all-time-high 2026 results
HBM back-end entry	Not mentioned	HBM-dedicated BX burn-in tester is “under consideration” only — Techwing and Advantest have already moved. Late-mover risk

1-2. Exicon (092870 KQ)

Item	Consensus comp	SemiScope addition
2024 results	Not mentioned	Revenue KRW 31.6B (-61.6% YoY), operating loss KRW -15.9B — starting point is a deep cyclical trough
CLT sole supply	Not mentioned	Samsung cleared final CLT qualification in late 2024; single supplier of LF tester from 2025 — much more concrete than the comp’s vague “Samsung partnership” framing
Cumulative orders (Oct 2025-Mar 2026)	Not mentioned	KRW 48.8B (CLT/Burn-in) + KRW 30.2B (SSD/CLT integrated) ≈ KRW 79B — about 2.5x of 2024 revenue, in five months of bookings
2026 guidance	“Afterthought until Samsung CXL CapEx confirmed”	Company guides to first KRW 100B+ revenue year and full swing-to-profit in 2026
CLT technology edge	Not mentioned	11,520-parallel processing (vs ~500-parallel legacy), at least a 2-year technology lead vs competitors

If you fold these in, Exicon stops being a “Samsung-CXL-dependent afterthought” and becomes “single-source CLT supplier entering its J-curve.” The consensus comp’s conclusion needs partial correction.

1-3. OpenEdge Technology (394280 KQ)

Item	Consensus comp	SemiScope addition
2024-2025 results	“Deepest moat but low CXL revenue visibility”	2024 revenue -21.8%, operating loss KRW -24.3B (loss widened); 3Q YTD 2025 cumulative loss KRW -21.3B — the “long-dated option” framing should be read more conservatively
License ASP	Not mentioned	Avg ~$1.1M per deal, up sharply from prior quarter ~$0.7M — leading-node IP mix expanding
LPDDR6 + Samsung 4nm	Not mentioned	Core new IP under multi-customer engagement in 2025
UCIe IP	“Under development”	Controller IP development complete and in validation; PHY in design start — more specific stage than the comp implies
Royalty revenue	“Low CXL visibility”	1H 2025 royalty mix 0.4% (KRW 0.029B) — given the lag from license to volume, the J-curve inflection point likely sits in 2026-2027 or later
Break-even timing	Not mentioned	Korea Investment models BEP in 2026 vs Shinhan models +87.5% revenue growth in 2025 — the consensus dispersion is unusually wide

2. Critical Re-Evaluation of the Consensus Comp

2-1. “OpenEdge has the deepest technology moat”

Partial agreement. The design-in switching cost on hard IP and the Memory Subsystem integration capability inside Korea is effectively monopolistic, and that part is fine. But against Synopsys and Cadence on a global comparison the gap is meaningful, and silicon-proven track record at leading nodes (N3/N2) is well behind.

“Deepest moat” should be read as “deepest moat within Korea.” OpenEdge’s moat reads less as a global multi-bagger candidate and more as a quality compounder anchored to the Korean AI/ASIC ecosystem.

2-2. “Neosem is the most genuinely irreplaceable name in CXL”

Agreed, conditionally. First-mover on CXL 1.1/2.0 plus the device-validation history with Samsung is the strongest single asset right now. But the comp under-weights the probability that CXL 3.1 introduces a dual-sourcing policy.

Implication: in a CXL 3.1 50:50 split scenario between Exicon and Neosem, Neosem’s “irreplaceability premium” gets partially diluted.

2-3. “Exicon’s Samsung relationship is strong but CXL purity and lead are weak — afterthought”

Partial agreement → active re-interpretation. The CXL-purity statement is factually correct, but this report views CLT — single-source, 11,520-parallel capacity, Samsung final-qual cleared in late 2024 — as forming a J-curve thesis independent of CXL as a Samsung DRAM back-end efficiency tool.

Through the CXL prism, Exicon is an afterthought. Through the DRAM back-end ATE prism, Exicon has the strongest near-term momentum. Both prisms are operating simultaneously, so Exicon should re-rank one tier higher than the consensus places it.

2-4. “Asymmetry: Neosem most balanced, OpenEdge long option, Exicon afterthought”

The framing collapses time horizons. Disaggregated:

Short term (6-12 months) momentum: Exicon > Neosem > OpenEdge. Exicon’s KRW 79B cumulative bookings + KRW 100B revenue guidance is the strongest signal.
Mid term (1-2 years) CXL cycle: Neosem > Exicon > OpenEdge. Agree with the consensus.
Long term (3-5 years) IP platform: OpenEdge > Neosem > Exicon. Agree with the consensus.

3. Three-Name Comparison Table

3-1. Financials

Item	Neosem	Exicon	OpenEdge
2024 revenue (KRW B)	105.2	31.6	15.3
2025E revenue (KRW B, prelim)	63.9 (-39.3%)	~60-70 (rebounding)	Wide range (Shinhan KRW 40.4B vs KI conservative)
2024 OP (KRW B)	16.5	-15.9	-24.3
2025E OP	4.1 (prelim)	Swing-to-profit attempt (1H -8.6)	Sustained loss (3Q YTD -21.3)
2026E guidance	“All-time-high revenue”	“KRW 100B+ revenue, swing to profit”	BEP (Korea Investment model)
Loss exposure	Stays profitable, but OPM compressed to 6.4%	2024 deep loss → 2026 recovery	Chronic R&D losses → long-dated BEP

3-2. Business & technology

Item	Neosem	Exicon	OpenEdge
Business model	Equipment (ATE)	Equipment (ATE)	IP / EDA
Core sole-source position	Gen5 SSD Tester (Advantest exited)	CLT (11,520-parallel, Samsung qualified)	LPDDR5X / LPDDR6 IP (within Korea)
First-mover area	CXL 1.1 / 2.0 mass-production tester	CLT (LF memory tester)	NPU + Memory Subsystem integrated IP
Late-mover area	HBM inspection equipment	CXL segment	Leading-node (N3/N2) memory IP
Revenue-recognition lag	Short (6-9 months from order)	Short (6-9 months from order)	Long (license recognized immediately, royalty 2-4 years out)
Customer mix	Samsung, SK hynix, Micron	Samsung (dominant)	Diversified globally and in Korea

3-3. Trend exposure summary

Trend	Neosem	Exicon	OpenEdge
Gen6 SSD (PCIe 6.0)	Strong tailwind	Tailwind	Neutral
CXL 2.0 → 3.1	Strong tailwind	Tailwind	Tailwind (indirect)
HBM4 / HBM4E	Neutral	Tailwind (indirect)	Neutral
LPDDR6	Neutral	Neutral	Strong tailwind
AI-inference ASIC diversification	Tailwind	Tailwind	Strong tailwind
Chiplet (UCIe)	Neutral	Neutral	Tailwind → Strong
Automotive ADAS ASIC	Neutral	Neutral	Strong tailwind
Memory CapEx cycle	High beta	Highest beta	Low beta

4. Scenario Analysis (All Three, Same Lens)

Scenario A — Memory CapEx normalizes + CXL 3.1 ramps (Bull)

Korean memory CapEx normalizes in 2026 → back-end ATE order cycle recovers.
Samsung CXL 3.1 line goes live; dual-sourcing policy splits Neosem and Exicon.
Beneficiary intensity: Exicon ≥ Neosem > OpenEdge — equipment names track cycle directly; OpenEdge is lagged by IP-to-volume conversion.

Scenario B — AI inference ASIC + automotive ASIC explosion (Bull)

Design-house diversification accelerates across AI inference and ADAS.
LPDDR6 + UCIe adoption accelerates → OpenEdge license ASP compounds.
Beneficiary intensity: OpenEdge > Neosem > Exicon — OpenEdge is the direct IP-diversification beneficiary; equipment names benefit only indirectly.

Scenario C — Memory CapEx recovery delayed + R&D burn accelerates (Bear)

Samsung CapEx slows, memory pricing stays soft.
All three stay under R&D pressure with poor revenue visibility.
Damage intensity: Neosem > Exicon ≥ OpenEdge — Neosem most exposed to cycle recovery; OpenEdge already in loss so marginal incremental damage is bounded.

Scenario D — Global IP / ATE leaders accelerate Korea entry (Bear)

Synopsys / Cadence expand share in Korean leading-node IP; Advantest re-enters SSD ATE.
Damage intensity: OpenEdge > Neosem > Exicon — OpenEdge most exposed to global competition; Exicon’s CLT 11,520-parallel barrier holds the longest.

5. Action Guide for Allocators

5-1. Per-name action map

Name	Action	Buy trigger	Sell / trim trigger
Exicon	Near-term J-curve bet / Core candidate	1Q26 swing-to-profit stability confirmed	Signal that CLT sole-source ends (competitor entry) / Samsung DRAM CapEx slows
Neosem	Enter after 1Q26 print / cycle-turnaround bet	1Q26 revenue recovers above KRW 20B + first CXL 3.1 mass-production order	HBM inspection-tool entry fails + dual-sourcing signal in Gen6
OpenEdge	Scaled accumulation / option position	First LPDDR6 + Samsung 4nm license disclosed + royalty mix reaches 5%	1H 2026 loss widens further + R&D headcount cost steps from KRW 11B → KRW 13B+

5-2. Where SemiScope diverges from the consensus comp

Item	Consensus comp	SemiScope (re-rank)
Core #1	Neosem	Exicon (near-term momentum) — or Neosem after 1Q26 print
Long option	OpenEdge	OpenEdge (agree)
Afterthought	Exicon	Exicon is in fact the #1 candidate on near-term momentum (re-evaluated outside the CXL prism)

6. Final Note (Allocator’s Frame)

The consensus comp ranks the three names through a single prism — CXL substitutability — and through that prism the conclusion (Neosem = Core, OpenEdge = option, Exicon = afterthought) is internally coherent. But once you fold in the 2026 earnings data and the order-disclosure flow, the picture shifts.

Exicon, viewed outside the CXL prism, is the strongest near-term momentum name in this trio. Single-source CLT, Samsung final-qual cleared in late 2024, KRW 79B cumulative bookings, and KRW 100B+ revenue guidance form a clean J-curve thesis. Low CXL exposure is not a weakness here — it is the strength of an independent thesis built on Samsung DRAM back-end efficiency.
Neosem is a name where consensus has already reset once on the 2025 revenue collapse. 1Q26 is the first revenue-recovery confirmation print; before that, this remains a cycle bet. The first CXL 3.1 mass-production disclosure is the entry-confirmation signal.
OpenEdge — agree with the consensus framing, but the 2025 widened loss and 0.4% royalty mix imply the J-curve inflection sits further out than the framing suggests. The 2026 BEP-or-not print is the watershed for the long-term valuation.

Final recommendation: Rather than collapsing the three names into a single 1-2-3 ranking, run them as time-horizon-separated bets. Exicon = short term, Neosem = mid term, OpenEdge = long-dated option. Layered exposure by timeframe delivers the best risk-adjusted setup of the available framings.

Appendix — Exicon Deep Profile

Snapshot

Core products: CLT (Chambered Low-frequency memory Tester) at 11,520 parallel — next-gen DRAM stability tester; Gen5 SSD Tester (Samsung-supplied); Burn-in Tester; CXL 2.0 Tester; non-memory testers (SoC / CIS / DDI).
Margins / track record: 2024 revenue KRW 31.6B / operating loss KRW -15.9B (loss-making). 1H 2025 cumulative operating loss KRW -8.6B. Cumulative new orders Oct 2025 - Mar 2026 ≈ KRW 79B (CLT / Burn-in / SSD). Both company and sell-side guide to first KRW 100B+ revenue year + full swing-to-profit in 2026.
Technology moat: CLT 11,520-parallel processing (~20x prior-gen 500-parallel). Samsung final qualification cleared in late 2024, sole supplier of LF tester since 2025; estimated technology lead at least 2 years vs competitors.
Investment view: Event-driven turnaround cycle name. Exited the 2024 trough via single-source CLT and large-order J-curve entry. Highest exposure to Samsung DRAM CapEx among Korean back-end ATE names.

Customer landscape

Stage	Customer	Product / process	Status
Production	Samsung	CLT (DRAM LF tester, sole supplier)	In production. KRW 20.4B + KRW 19.6B + KRW 8.8B = KRW 48.8B total disclosed in Oct-Nov 2025
Production	Samsung	CLT + SSD Tester combined supply	Additional KRW 30.2B disclosed in Mar 2026 (~95.5% of latest reported revenue)
Production	Samsung	Gen5 SSD Tester	In volume
Production	Samsung	Burn-in Tester	In volume
In progress	Samsung	CXL 2.0 Tester (Neosem dual-source potential)	In development + adoption push
In progress	Samsung	Gen6 SSD Tester	In R&D
In progress	Samsung S.LSI	DDI Tester, AP Tester	In development off CIS-tester base
Potential	SK hynix	Memory Tester	Limited share, expansion under exploration

Quantum-jump triggers

Trigger #1 — CLT volume cycle entry + 20+ cumulative installs. Per company guidance, hitting ~20 cumulative CLT installs at Samsung DRAM lines in 2026 supports KRW 100B+ revenue. 2024 revenue KRW 31.6B → 2026 KRW 100B+ implies ~3.2x topline + swing-to-profit.
Trigger #2 — CXL 3.1 dual-vendor entry. If Samsung adopts a dual-sourcing policy on CXL 3.1, Exicon could capture ~50% of equipment supply alongside Neosem. CXL ASP runs ~2-3x SSD Tester levels, implying meaningful incremental revenue.
Trigger #3 — Gen6 SSD Tester R&D → volume. R&D-line Gen6 SSD Tester supply could materialize in 2026, with volume entry in 2027. Risk: Neosem retains pole position given Advantest exit.
Trigger #4 — Non-memory (SoC / AP / DDI) tester volume recognition. CIS-tester-derived DDI / AP testers winning a Samsung S.LSI or external fabless design-in would meaningfully de-risk the cycle dependency.

Risks & watchlist

Single-customer concentration. Revenue is overwhelmingly Samsung-dependent — 2024’s -61.6% revenue decline is the cleanest illustration. Any Samsung CapEx slowdown flows directly into a single quarter.
CLT competitor catch-up. No competitor is currently visible at 11,520-parallel chamber engineering, but a 2-year window is not infinite; monitor Dlight / UnTest Sci (and others) for entry signals.
CXL 3.1 first-mover not secured. Neosem retains the lead in CXL. If Exicon stays second-source through CXL 3.1, the CXL-cycle alpha is capped.

Five checkpoints for the next 1-2 quarters

1Q26 print — magnitude of the swing to profit. How much of the KRW 79B order book recognizes as revenue and operating profit. The cleanest stability check.
Cumulative CLT install count for 2026. Company guides to ~20 units. Quarterly tracking of whether installs follow the trajectory.
CXL 3.1 Tester Samsung qualification disclosure timing. Most likely 1H 2026. Pass = dual-source seat secured. Miss = no CXL-cycle participation.
HBM-line entry for inspection equipment. Whether HBM4E back-end-validation burden flows into CLT / Burn-in demand. A formal HBM-spec disclosure from the company would be the meaningful signal.
Non-memory (DDI / AP) tester revenue disclosure. A separate disclosure with the line item exceeding 10% of revenue is the quantitative diversification signal.